Strategic Opportunities BD potential with large pharma partners through their established design and manufacturing of injectable drug delivery systems, highlighting opportunities to offer platform products and integrated services (human factors, regulatory, final assembly, packaging) to accelerate time to market.

Global Footprint Leverage their UK headquarters and manufacturing in Malaysia with US, German, and French subsidiaries to position cross-region collaborations, regional supply chain resilience programs, and multi-market sterile device rollouts for partner portfolios.

Sustainability Angle Capitalize on ReSCiD remanufacturing initiative and sustainability focus to propose eco-friendly packaging, material reductions, and circular economy solutions as differentiators for partner products seeking greener drug delivery devices.

Acquisition Context BD’s reported acquisition interest from BD & Co. signals strategic value and market consolidation dynamics; approach opportunities with BD as potential channel or collaborator, while also preparing complementary offerings to satisfy larger buyer due diligence.

Market Positioning Position as a trusted, patient-centric innovator with end-to-end support from concept to market; offer ready-made regulatory, human factors, and manufacturing acceleration services to reduce risk and cost for pharma/biotech partners pursuing speed to market.